A Clinical Study of 6MW3211 Monotherapy or Combination Therapy for AML or MDS
This study is aimed to evaluate the efficacy, safety, immunogenicity and pharmkinetics, pharmacodynamics of 6MW3211 as monotherapy and in combination with AZA or AZA plus VEN in patients with AML/MDS.
Acute Myeloid Leukemia|Myelodysplastic Syndrome
DRUG: 6MW3211 injection with Intravenous Infusion
CCR, Compound complete response rate, 1 year|ORR, Objective Response Rate, 1 year|phase II: safety, to evaluate the percentage of participants with adverse events and serious adverse events of 6MW3211 combination therapy in AML and MDS, Up to 28 days post last dose
AE, All the adverse events, Up to 28 days post last dose|DoCR, Duration of complete response, 1 year|RFS, Relapse-free survival, 1 year|EFS, Event-free survival, 1 year|OS, Overall survival, 1 year|PK Parameter, The area under the curve (AUC), 1 year|Cmax, Maximum concentration, 1 year|Tmax, Time at which maximum concentration, 1 year|T1/2, The half life, 1 year
This study is a phase I/II study to evaluate the pharmacokinetics, pharmacodynamics, efficacy and safety of 6MW3211 monotherapy or combined with AZA or AZA plus VEN in patients with AML and MDS. There will be 2 parts of this study. The phase Ib is about monotherapy of 6MW3211 and Phase II is designed to evaluate the safety and efficacy of 6MW3211 combined with AZA or AZA plus VEN in patients with relapse/refractory and newly diagnosed AML and MDS.